Method for preparing antibody

By using pseudolentiviruses or retroviral vectors to deliver antigens in subjects, the problems of complex and costly antibody preparation in existing technologies have been solved, achieving efficient and low-cost antibody preparation.

WO2026233365A1PCT designated stage Publication Date: 2026-11-12SHENZHEN GENOCURY BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095188
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing antibody preparation methods are complex and costly, especially since transmembrane proteins and conformation-dependent proteins are difficult to express and purify effectively in vitro, resulting in poor immunization effects.

Method used

Using pseudolentiviral or retroviral vectors, carrying exogenous polynucleotides encoding antigens and viral glycoproteins or their functional fragments, the antigens are delivered directly into the subject's body and expressed, inducing an immune response to produce antibodies.

Benefits of technology

It simplifies the antibody preparation process, reduces costs, and improves efficiency. In particular, it enables the stable expression and purification of antigens that are difficult to express in vitro, solving the problems of high preparation costs and complex operations, and achieving efficient antibody preparation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026095188_12112026_PF_FP_ABST
    Figure CN2026095188_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the field of antibody preparation, and specifically relates to a method for preparing an antibody in vivo in a subject. The method comprises administering a pseudotyped lentiviral vector or a retroviral vector to a subject, wherein the pseudotyped lentiviral vector or the retroviral vector comprises an exogenous polynucleotide encoding an antigen and a viral glycoprotein or a functional fragment thereof, and the antigen is able to specifically bind to the antibody.
Need to check novelty before this filing date? Find Prior Art

Description

A method for preparing antibodies Technical Field

[0001] This invention relates to the field of antibody preparation, and more specifically to a method for preparing antibodies in a subject. Background Technology

[0002] Antibodies, as an important class of biological macromolecules, play a wide role in disease diagnosis, treatment, and basic research. Currently, the most common method for obtaining specific antibodies is through animal immunization. This method typically includes the following steps: First, the target antigen is prepared in vitro using a recombinant protein expression system (such as E. coli, mammalian cells, yeast, or insect cells); second, the expression product is purified to obtain antigens with high purity and biological activity; finally, the antigen is repeatedly injected into experimental animals (such as mice, rats, or rabbits) to induce their immune systems to produce specific antibodies, and the desired antibodies are obtained by collecting serum or preparing hybridoma cells.

[0003] Although the aforementioned technical approaches have been widely adopted, several challenges remain in practice. First, the in vitro expression and purification of antigens is complex, especially for transmembrane proteins, glycoproteins, or proteins with strong conformational dependence, often making it difficult to obtain purified products with their native conformation. Second, protein purification typically requires multiple chromatographic steps, including affinity chromatography, ion exchange chromatography, and molecular sieve chromatography, which are complex and costly. Furthermore, to ensure immunization efficacy, appropriate modification of the antigen or its use in conjunction with adjuvants is necessary, further increasing experimental costs and technical difficulty.

[0004] Therefore, how to simplify the antigen preparation steps in antibody preparation, reduce antigen preparation costs, and improve antibody acquisition efficiency remains a technical problem that urgently needs to be solved in this field. Summary of the Invention

[0005] In view of this, one aspect of the present invention provides a pseudotyped lentiviral vector (LVV) or retroviral vector (RVV) for preparing antibodies in a subject, comprising:

[0006] A. The pseudotyped LVV or RVV contains an exogenous polynucleotide encoding an antigen; and,

[0007] B. The surface of the pseudo-LVV or RVV contains viral glycoproteins or their functional fragments, or variants (Mutated G), or modified G.

[0008] In some embodiments of the present invention, the antigen described in A includes at least one of: A) intracellular expressed antigen, B) cell surface expressed antigen, and C) secreted antigen.

[0009] In some embodiments of the present invention,

[0010] A) The intracellular expressed antigens include at least one of the following: MAGE family proteins, NY-ESO-1 (LAGE-1), WT1 (Wilms' tumor 1 protein), p53, hTERT (telomerase reverse transcriptase), tyrosinase, BCR-ABL, ETV6-AML, mutant Ras, HPV E6 / E7 protein, HIV Gag p24 protein, EBV EBNA1 protein, influenza virus nucleoprotein, and Survivin;

[0011] B) The cell surface expressed antigens include CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD28, CD30, CD33, CD37, CD38, CD40, CD40L, CD44, CD44v6, CD46, CD47, CD52, CD54, CD56, CD70, CD73, CD79α, CD79β, CD80, CD97, CD123, CD171, CLEC12A (CLL-1), CS-1, BAFF-R, PD-1 (CD279), PD-L1 (CD274), PD-L2, EGFR (ErbB-1 / HER1), HER2 / neu (ErbB-2), ErbB3, ErbB4, KIT (CD117), and FLT3. (CD135), TSHR, GPRC5D, ADRB3, EPCAM (EGP-40), MUC1, MUC16 (CA-125), CEA (CEACAM5), Nectin-4, CD138 (Syndecan-1), Mesothelin (MSLN), ASGPR, DLL3, Nectin4, Claudin18.2, B7H3, GCC, GUCY2C, viral glycoprotein, FAP, PSMA, ROR1, BCMA, uPAR, FolateRα, FolateRβ, VCAM-1 (CD106), GD2, GD3, Fucosyl-GM1, Tn-Ag, Lewis-Y, GloboH, sLe, CD127 (IL-7Rα), TLR4 (Toll-like receptor 4), TIM-3, Integrin αvβ3, and at least one of IGF1R; and

[0012] C) The secreted antigens include at least one of VEGF (vascular endothelial growth factor), IL-2 (interleukin-2), TGF-β (transforming growth factor-β), APRIL (a proliferation-inducing ligand, TNFSF13), IL-1Ra (interleukin-1 receptor antagonist), IL-8 (CXCL8), CCL2 (MCP-1), IL-6, IFN-γ, and GM-CSF.

[0013] In some embodiments of the present invention, the antigen includes a cell surface antigen, which includes at least one of viral glycoprotein, CD19, CD20, CD33, MSLN, CD79α, CD79β, CD8, ASGPR, BCMA, CEA, uPAR, DLL3, GCC, Nectin4, HER2, Claudin18.2, B7H3, and GUCY2C.

[0014] In some embodiments of the present invention, the viral glycoprotein or its functional fragment, variant, or modified form described in B. is selected from: vesicular stomatitis virus glycoprotein or its functional fragment, variant, or modified form; Nipah virus (NiV) glycoprotein G or its functional fragment, variant, or modified form; measles virus glycoprotein H or its functional fragment, variant, or modified form; lentivirus glycoprotein or its functional fragment, variant, or modified form; rabies virus glycoprotein (RVG) or its functional fragment, variant, or modified form; and gibberish leukemia virus glycoprotein. GaLV or its functional fragments or variants or modifications thereof, biphilic murine leukemia virus glycoprotein (MLV-A) or its functional fragments or variants or modifications thereof, feline endogenous virus (RD114) glycoprotein or its functional fragments or variants or modifications thereof, avian plague virus (FPV) glycoprotein or its functional fragments or variants or modifications thereof, Ebola virus (EboV) glycoprotein or its functional fragments or variants or modifications thereof, and T-cell choroid plexus meningitis virus (LCMV) glycoprotein or its functional fragments or variants or modifications thereof;

[0015] More preferably, the vesicular stomatitis virus glycoprotein is selected from: vesicular stomatitis virus Indiana strain glycoprotein, vesicular stomatitis virus Cocal strain glycoprotein, vesicular stomatitis virus Maraba strain glycoprotein, vesicular stomatitis virus Morreton strain glycoprotein, vesicular stomatitis virus Alagoas strain glycoprotein, and vesicular stomatitis virus New... The following vesicular stomatitis virus (VSV) strains contain glycoproteins: Jersey, Carajas, Chandipura, Eptesicus, Isfahan, Jurona, Malpais, Perinet, Piry, Radi, Rhinolopus, and Yug Bogdanovac.

[0016] In some embodiments of the present invention, the viral glycoprotein or its functional fragment, or a variant thereof, or a modified version thereof comprises:

[0017] a. A first mutation that inhibits the ability of its receptor LDL-R to specifically bind; and / or,

[0018] b. A second mutation that enhances the ability to antagonize complement inactivation.

[0019] In some embodiments of the present invention, the pseudotype LVV or RVV comprises: vesicular stomatitis virus Indiana strain glycoprotein (wild-type VSV-G) or a functional fragment thereof, or a variant thereof (VSV-G variant), or a modified form thereof (VSV-G modified form); or vesicular stomatitis virus Cocal strain glycoprotein (wild-type Cocal-G) or a functional fragment thereof, or a variant thereof (Cocal-G variant), or a modified form thereof (Cocal-G modified form);

[0020] The amino acid sequence of the wild-type VSV-G is shown in SEQ ID NO:1; the amino acid sequence of the wild-type Cocal-G is shown in SEQ ID NO:2.

[0021] In some embodiments of the present invention, the site of the first mutation mentioned in a. is:

[0022] 1) Substitution or deletion of amino acids at positions 8, 9, 10, 47, 50, 51, 183, 179, 180, 182, 184, 209, 347, 350, 352, 353 and / or 354 in SEQ ID NO:1 or SEQ ID NO:2; deletion of amino acids at positions 1-18, 19-36, 37-51, 314-384, 321-374, 331-364, 344-354 and / or 345-353; or,

[0023] 2) After best global alignment with SEQ ID NO:1 or SEQ ID NO:2, the substitution or deletion of amino acids at positions 8, 9, 10, 47, 50, 51, 183, 179, 180, 182, 184, 209, 347, 350, 352, 353 and / or 354, and the deletion of amino acids at positions 1-18, 19-36, 37-51, 314-384, 321-374, 331-364, 344-354 and / or 345-353.

[0024] Preferably, the first mutation is selected from one or more of the following mutations:

[0025] 1) Deletion of amino acids 331-364, deletion of amino acids 344-354, substitution or deletion of K47, substitution of I331, substitution of R354, substitution of Y209, and substitution of I / V182 located in SEQ ID NO:1 or SEQ ID NO:2; or

[0026] 2) After best global alignment with SEQ ID NO:1 or SEQ ID NO:2, the amino acid positions 331-364 and 344-354 of the corresponding SEQ ID NO:1 or SEQ ID NO:2 are deleted, K47 is replaced or deleted, I331 is replaced, R354 is replaced, Y209 is replaced, and I / V182 is replaced.

[0027] More preferably, the first mutation is:

[0028] 1) K47 is missing in SEQ ID NO:1 or SEQ ID NO:2; or

[0029] 2) After best global alignment with SEQ ID NO:1 or SEQ ID NO:2, K47 is missing at the position equivalent to SEQ ID NO:1 or SEQ ID NO:2.

[0030] In some embodiments of the present invention, the enhanced ability to antagonize complement inactivation described in b. is relative to the absence of the second mutation.

[0031] In some embodiments of the present invention, the second mutation site described in b. is: 1) amino acids 50, 146, 214 and / or 352 located in SEQ ID NO:1 or SEQ ID NO:2; or,

[0032] 2) The amino acid located at the 50th, 146th, 214th and / or 352nd amino acid positions corresponding to SEQ ID NO:1 or SEQ ID NO:2 after best global alignment with SEQ ID NO:1 or SEQ ID NO:2.

[0033] Preferably, the mutation at the site is selected from amino acid substitutions, deletions, and insertions;

[0034] More preferably, the mutation at the site is an amino acid substitution.

[0035] In some embodiments of the present invention, the second mutation described in b. is selected from a combination of mutations at the following sites:

[0036] 1) Substitution of (1) T / K214 and T352 located in SEQ ID NO:1 or SEQ ID NO:2, or (2) Substitution of T / K214, T352, K50 and S146; or

[0037] 2) After the best global alignment with SEQ ID NO:1 or SEQ ID NO:2, the substitutions of (1) T / K214 and T352, or (2) T / K214, T352, K50 and S146, are located at the equivalent of SEQ ID NO:1 or SEQ ID NO:2.

[0038] Preferably, in b., the second mutation is selected from a combination of mutations at the following sites:

[0039] 1) (1) T / K214N and T352A located in SEQ ID NO:1 or SEQ ID NO:2, or (2) T / K214N, T352A, K50T and S146T; or

[0040] 2) After the best global alignment with SEQ ID NO:1 or SEQ ID NO:2, it is located at (1) T / K214N and T352A, or (2) T / K214N, T352A, K50T and S146T, which are equivalent to SEQ ID NO:1 or SEQ ID NO:2.

[0041] In some embodiments of the present invention, the surface of the pseudo-LVV or RVV contains viral glycoproteins or their functional fragments, variants, or modifications thereof, whose amino acid sequences are shown in any one of SEQ ID NO:3-14;

[0042] Compared to SEQ ID NO:1, SEQ ID NO:3 contains a K47 deletion;

[0043] SEQ ID NO:4 contains R354Q, relative to SEQ ID NO:1;

[0044] Compared to SEQ ID NO:1, SEQ ID NO:5 contains K47 deletion, T214N, and T352A;

[0045] Compared to SEQ ID NO:1, SEQ ID NO:6 contains K47 deletion, T214N, T352A, K50T, and S146T;

[0046] Compared to SEQ ID NO:1, SEQ ID NO:7 includes R354Q, T214N, and T352A;

[0047] Compared to SEQ ID NO:1, SEQ ID NO:8 includes R354Q, T214N, T352A, K50T, and S146T;

[0048] Compared to SEQ ID NO:2, SEQ ID NO:9 contains a K47 deletion;

[0049] SEQ ID NO:10 contains R354Q, relative to SEQ ID NO:2;

[0050] Compared to SEQ ID NO:2, SEQ ID NO:11 contains K47 deletion, K214N, and T352A;

[0051] Compared to SEQ ID NO:2, SEQ ID NO:12 contains K47 deletion, K214N, T352A, K50T, and S146T;

[0052] Compared to SEQ ID NO:2, SEQ ID NO:13 includes R354Q, K214N, and T352A;

[0053] Compared to SEQ ID NO:2, SEQ ID NO:14 includes R354Q, K214N, T352A, K50T and S146T.

[0054] In another aspect, the present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and any of the aforementioned pseudoforms of LVV or RVV provided by the present invention.

[0055] In another aspect, the present invention also provides the application of any of the aforementioned pseudotypes of LVV or RVV in the preparation of antibodies in subjects.

[0056] In another aspect, the present invention also provides a method for preparing antibodies, comprising administering to a subject any of the aforementioned pseudotypes of LVV or RVV or the aforementioned pharmaceutical composition.

[0057] In some embodiments of the present invention, in the method of preparing antibodies, the administration is selected from at least one of enteral routes, inhalational routes, topical and mucosal routes, parental routes, and modified-release and implantable methods; the parental routes include intravenous bolus, intravenous infusion, intramuscular (IM), subcutaneous (SC), intradermal (ID), intra-arterial (IA), intra-portal (PV), intraosseous (IO), intraperitoneal (IP), intrapleural / thoracic (IT), epidural (EP), subarachnoid (IT), intracranial (IC), intraventricular (ICV), intra-articular (IA-aticular), intraocular (IVT), intralesional, and intratumoral administration.

[0058] In some embodiments of the present invention, the subjects include humans (Homo sapiens), non-human primates (NHP), other mammals, and other vertebrates.

[0059] In some embodiments of the present invention, the non-human primates include macaques (Macaca mulatta), chimpanzees (Pan troglodytes), cynomolgus monkeys (Macaca fascicularis), and rhesus monkeys (Macaca mulatta); the other mammals include mice (Mus musculus), rats (Rattus norvegicus), Chinese hamsters (Cricetulus griseus), rabbits (Oryctolagus cuniculus), cattle (Bos taurus), sheep (Ovis aries), goats (Capra hircus), Bactrian camels (Camelus bactrianus), alpacas (Vicugna pacos), and domestic horses (Equus ferus caballus);

[0060] The other vertebrates mentioned include chondrichthyes.

[0061] In some embodiments of the present invention, the pseudo-LVV or RVV is administered to the subject no more than once, no more than twice, no more than three times, no more than four times, or no more than five times.

[0062] In some embodiments of the present invention, the subject is given the pseudo-LVV or RVV once, twice, or three times.

[0063] In some embodiments of the present invention, after administering the pseudo-LVV or RVV to the subject, the subject is given the pseudo-LVV or RVV again after a one-week interval, for a total of no more than three times.

[0064] In some embodiments of the present invention, the antibodies prepared in the subject include IgM antibodies, IgA antibodies, and IgG antibodies.

[0065] In some embodiments of the present invention, the antibody prepared in the subject is an IgG antibody.

[0066] Furthermore, the present invention also provides a method for preparing antibodies, comprising:

[0067] S1. Prepare antibodies in the subject using any of the aforementioned methods for preparing antibodies in the subject; and

[0068] S2. Collect the subject's bodily fluids, and separate and collect the antibodies from the bodily fluids.

[0069] In some embodiments of the present invention, in S2, the body fluid includes blood and / or ascites.

[0070] In some embodiments of the present invention, in S2, the bodily fluid is blood, and the method further includes:

[0071] S21. Separate serum or plasma from the blood; and

[0072] S22. Isolate and collect the antibody from the serum or plasma.

[0073] In some embodiments of the present invention, the method further includes:

[0074] S3. Purify the antibody. Beneficial effects

[0075] This invention provides a pseudolentiviral vector (LVV) or retroviral vector (RVV) for preparing antibodies in a subject, and a method for preparing antibodies in a subject, comprising administering to the subject any of the aforementioned pseudolentiviral vectors or RVVs provided by this invention, wherein the pseudolentiviral vector or RVV contains an exogenous polynucleotide encoding an antigen. In the subject, the pseudolentiviral vector or RVV:

[0076] 1. It can be phagocytosed by cells with phagocytic capacity, such as spleen cells (including splenic macrophages and splenic neutrophils) or hepatocytes (including Kupffer cells), to enter the cell and deliver and stably express antigens; or,

[0077] 2. It enters the cell through endocytosis triggered by the binding of its contained viral glycoproteins or their variants to viral glycoprotein receptors on the cell surface, delivers and expresses antigens, and induces an immune response in the animal body, thereby producing antibodies.

[0078] The method provided by this invention does not require:

[0079] ① Expressing and purifying antigens in vitro in animals;

[0080] ② Multiple immunizations of animals are simpler to perform, lower in cost, and more efficient.

[0081] ③ The antigen can be stably expressed in the subject's body; and

[0082] ④ More importantly, some specific antigens, including but not limited to antigens with hydrophobic transmembrane domains, such as viral glycoproteins, face technical challenges in in vitro preparation, such as low expression levels, difficulty in purification, or differences in the three-dimensional domains of the prepared antigens compared to the natural antigens.

[0083] The method provided by this invention can directly deliver, express, and prepare the aforementioned specific antigens in animals, effectively solving the technical problems of high preparation costs, complex operations, and poor immunization effects of the prepared antigens on animals caused by the difficulty in effectively expressing and purifying the aforementioned specific antigens in vitro, thus making it difficult to effectively prepare antibodies.

[0084] In this article:

[0085] Blood: Blood is a bodily fluid in the circulatory system, responsible for transporting oxygen and nutrients to all cells in the body, removing metabolic waste, and participating in immune defense. Blood is composed of liquid components (plasma) and cellular components (red blood cells, white blood cells, and platelets).

[0086] "Serium": Serum is the product of plasma after removing clotting factors (mainly fibrinogen). It contains all proteins, electrolytes, antibodies, hormones, and exogenous substances (such as drugs and microorganisms) that do not participate in clotting. Serum is commonly used for immunological detection and biochemical analysis.

[0087] Methods for separating serum from animal blood are well known to those skilled in the art, including but not limited to:

[0088] (1) Collection: Collect whole blood in a blood collection tube without anticoagulant (or a serum collection tube with a coagulation promoter); (2) Coagulation: Let it stand at room temperature for 30–60 minutes to allow the blood to coagulate naturally; you can also gently rotate or invert it to promote clot formation, but avoid violent shaking to prevent hemolysis; (3) Centrifugation: After coagulation, place it in a centrifuge and centrifuge with the same parameters (about 1,000–2,000×g, 10–15 minutes, 4°C) to allow the blood clot to sink, and the supernatant is the serum; (4) Sampling: Carefully aspirate the serum with a Pasteur pipette, avoiding disturbing the blood clot.

[0089] "Plasma": Plasma is the liquid component of blood, accounting for about 55% of the total blood volume, and is light amber in color. Plasma contains water (about 90%), electrolytes, proteins (such as albumin, globulin, and fibrinogen), hormones, nutrients, and clotting factors, and is an important transport medium and homeostasis regulator in the body.

[0090] Methods for separating plasma from animal blood are well known to those skilled in the art, including but not limited to:

[0091] (1) Collection: Collect whole blood in a blood collection tube containing an anticoagulant (such as EDTA, heparin or sodium citrate) to prevent blood clotting; (2) Centrifugation: Place the collection tube in a centrifuge and centrifuge at about 1,000–2,000×g for 10–15 minutes (4°C). Blood cells will settle due to their higher density and form a lower cell cluster. The supernatant is plasma; (3) Sampling: Carefully aspirate the supernatant plasma using a Pasteur pipette or pipette and place it in a sterile container for later use.

[0092] "Purification": As used herein, "purification" refers to the process of removing non-target components from complex biological mixtures (such as cell lysates or culture supernatants) through a series of separation and enrichment steps to obtain a target protein with high purity and biological activity. Common purification strategies include affinity chromatography, which utilizes the specific binding of the target protein to solid-phase ligands; ion exchange chromatography based on charge difference; and size exclusion chromatography, which separates molecules based on size. Commonly used purification methods include, but are not limited to:

[0093] (1) Affinity Chromatography, such as (a) Protein A / G / L affinity chromatography, where Protein A and Protein G are immunoglobulin-binding proteins derived from Staphylococcus aureus and Streptococcus, which can efficiently capture IgG antibodies from various sources and are suitable for the preliminary purification of primary / secondary antibodies and monoclonal antibodies; and (b) antigen / specific ligand affinity chromatography, where specific ligand chromatography such as nickel chelate (IMAC) and glutathione affinity can be used for recombinant or fusion protein tags (such as His-tag, GST-tag) to achieve high-purity recovery; if the antigen-antibody pair is known, the purified antigen can be coupled to a solid matrix for the purification of homologous monoclonal or polyclonal antibodies;

[0094] (2) Precipitation methods, such as (a) Ammonium sulfate precipitation, in which ammonium sulfate is gradually added to a certain saturation (usually 30-50% saturation) to precipitate IgG and most plasma proteins, while the remaining small molecules and impurities remain in the supernatant; after resuspending the precipitate, it can be further purified or used directly in experiments; (b) Polyethylene glycol (PEG) precipitation, PEG can promote protein aggregation and precipitation by changing the hydrophobicity of the solvent, and is often used for the preliminary enrichment of polyclonal antibodies in cell culture supernatant or hybridoma cell culture medium. It is simple to operate and has little damage to antibody activity;

[0095] (3) Ion exchange chromatography (IEX) utilizes the difference in surface charge of proteins for separation and is divided into two types: cation exchange (CEX) and anion exchange (AEX). Under suitable pH conditions, IgG can bind to resins with opposite charges. By changing the salt concentration gradient (such as NaCl) or pH gradient, host proteins and nucleic acid impurities with similar opposite charges can be effectively removed. IEX is often used in conjunction with affinity chromatography to improve antibody purity and reduce endotoxin and host cell protein residues.

[0096] (4) Size-Exclusion Chromatography (SEC, also known as gel filtration chromatography) separates molecules based on their size, with larger molecules exiting the column first and smaller molecules exiting later. It is often used to remove impurities with very different molecular weights (such as small molecule salts, low molecular weight degradation products) and aggregates, and can also be used as a final polishing step to ensure the monodispersity of the product;

[0097] (5) Hydrophobic Interaction Chromatography (HIC) utilizes the interaction between the hydrophobic region on the protein surface and hydrophobic ligands under high salt conditions for separation. It is often used as a polishing process to remove aggregates and host proteins. The typical procedure is as follows: the sample is loaded onto the column under high concentration of kosmotropic salt (such as ammonium sulfate 1-2 M), non-target proteins bind first, and then the target antibody is eluted by reducing the salt concentration or adding organic modifiers in a gradient.

[0098] (6) Ultrafiltration / diafiltration concentration: This method utilizes a semi-permeable membrane to concentrate antibodies and exchange buffers. It can remove low molecular weight impurities before and after chromatography and perform desalting and buffer exchange on the final product.

[0099] (7) Mixed-mode chromatography combines chromatographic media with multiple interaction mechanisms (such as ion exchange + affinity, hydrophobic + ion exchange) to achieve multiple impurity removal and high-purity recovery in one step.

[0100] Subjects: refers to any living individual, including but not limited to humans, non-human primates, other mammals, other vertebrates, and other invertebrates; among them, humans (Homo sapiens) include human individuals of any age, sex, or health status, including healthy volunteers, patients, and clinical trial participants; non-human primates include but are not limited to macaques (Macaca mulatta), chimpanzees (Pan troglodytes), cynomolgus monkeys (Macaca fascicularis), and rhesus monkeys (Macaca mulatta); other mammals include but are not limited to mice (Mus musculus), rats (Rattus norvegicus), Chinese hamsters (Cricetulus griseus), rabbits (Oryctolagus cuniculus), cattle (Bos taurus), sheep (Ovis aries), goats (Capra hircus), Bactrian camels (Camelus bactrianus), alpacas (Vicugna pacos), and domestic horses (Equus ferus caballus); other vertebrates include but are not limited to cartilaginous fishes.

[0101] Endocytosis is a process by which substances enter a cell. In endocytosis, the substance to be taken in is surrounded by a region of the plasma membrane, which then buds inside the cell to form a vesicle containing the taken-in substance. Endocytosis can be classified into four types: receptor-mediated endocytosis (also known as clathrin-mediated endocytosis), caveolae, pinocytosis, and phagocytosis (Marsh M, Endocytosis. Oxford University Press. p.vii., 2001).

[0102] Phagocytosis is an active, energy-dependent endocytosis process in which cells use pseudopodia to encapsulate and internalize exogenous particles larger than approximately 0.5 μm in diameter, forming phagosomes, which then fuse with lysosomes to degrade the contents.

[0103] “Antigen”: The terms “antigen” and “Ag” refer to molecules capable of inducing an immune response. An induced immune response may include antibody production and / or activation of specific immune-competent cells. Macromolecules, including proteins, glycoproteins, and glycolipids, can be used as antigens. Antigens can be derived from recombinant or genomic DNA. As contemplated herein, antigens do not need to be (i) encoded solely by the full-length nucleotide sequence of a gene or (ii) entirely encoded by a gene. Antigens can be generated or synthesized, or they can be derived from biological samples. Such biological samples may include, but are not limited to, tissue samples, tumor samples, cells, or biological fluids.

[0104] In some embodiments of the present invention, the antigen includes, but is not limited to, at least one of: (a) intracellular expressed antigens, (b) cell surface expressed antigens, and (c) secreted antigens. Intracellular expressed antigens (also known as endogenous antigens) refer to proteins or polypeptides synthesized in the cytoplasm, organelles, or nucleus. These are degraded into short peptides by the proteasome and bind to MHC I molecules in the endoplasmic reticulum, subsequently being transported to the cell surface for use by CD8+. + Cytotoxic T lymphocytes recognize and mediate the killing of target cells. Cell surface antigens are proteins or glycoproteins embedded in or anchored to the plasma membrane, including receptors, membrane transporters, MHC molecules, and blood group antigens. These antigens can be directly recognized by B cell receptors or recognized by T cells on the surface of APC cells in the form of peptide-MHC complexes, triggering humoral or cellular immune responses. Secreted antigens are soluble molecules actively released into the extracellular environment by cells through the classical endoplasmic reticulum-Golgi apparatus pathway or exosome pathway, such as cytokines, chemokines, hormones, microbial toxins, or viral capsid proteins. These antigens can be directly neutralized by antibodies or taken up by APCs and presented to CD4⁺ helper T cells via MHC II molecules, initiating or regulating immune responses.

[0105] “Inhibition”: When referring to the ability of a viral glycoprotein to bind to its receptor (binding capacity) being “inhibited,” the term “inhibition” includes both the complete elimination of said binding capacity and a significant reduction in said binding capacity. In a specific embodiment, “significant reduction” means relative to (a) a wild-type viral glycoprotein or (b) a viral glycoprotein that does not contain the first mutation or modification provided by the present invention; “reduction” is selected from reductions of at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, at least 10%, at least 5%, at least 4%, at least 3%, at least 2%, and at least 1%.

[0106] For explanations of other terms mentioned in this article, please refer to patents WO2025209590A and WO2025011662A.

[0107] All publications, documents, and patents mentioned herein are hereby incorporated in their entirety by reference, as are each publication, document, or patent not specifically and individually indicated to be incorporated herein by reference in its entirety. In case of conflict, this application (including any definitions herein) shall prevail. However, any references, articles, publications, patents, patent publications, and patent applications cited herein are not and should not be construed as an admission or recommendation of any kind.

[0108] The section headings used in this article are for organizational purposes only and are not intended to limit the topics described. Attached Figure Description

[0109] Figure 1: A schematic diagram of the gene elements contained in the shuttle plasmid VSV-G in Example 1.

[0110] Figure 2: A bar chart showing the OD values ​​of plasma from mice (CTR, M1, M2, M3) that were not injected with the LVV-VSVG via the tail vein or were injected with the LVV-VSVG via the tail vein in Example 1, when diluted to 8000 times (Figure 2A) or 16000 times (Figure 2B).

[0111] Figure 3: This figure shows the results of detecting the antibody positivity rate in the plasma of mice (CTR, M1, M2, M3) that were not injected with the LVV-VSVG via the tail vein or were injected with the LVV-VSVG via the tail vein using flow cytometry on Day 14 in Example 1.

[0112] Figure 4: A schematic diagram of the gene elements contained in the shuttle plasmid BCMA in Example 2.

[0113] Figure 5: This figure shows the results of flow cytometry analysis on Day 14 of Example 2, to detect the antibody positivity rate in the plasma of mice (CTR, M1, M2, M3, M4) that were not injected with the tail vein or were injected with the tail vein of the LVV-BCMA.

[0114] Figure 6: Shuttle plasmid map.

[0115] Figure 7: The OD values ​​of serum from mice (control group, M1, M2, M3) at different dilutions were detected by ELISA on Day 7 and Day 14 in Example 3, whether they were injected with LVV-CD19 via the tail vein or not.

[0116] Figure 8: The OD values ​​of serum from mice (control group, M1, M2, M3) at different dilutions were detected by ELISA on Day 7 and Day 14 in Example 4, whether they were injected with LVV-BCMA via the tail vein or not. Detailed Implementation

[0117] The present invention and its technical effects will be clearly and completely described below with reference to embodiments, so as to fully understand the technical solution, the technical problem solved, and the beneficial effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments; other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.

[0118] Experimental methods not specifically described in the following examples were performed according to conventional methods and conditions known in the art, or according to the product instructions. Reagents and raw materials not specifically described in this invention are all commercially available. Example 1

[0119] The LVV-VSVG package contains a polynucleotide encoding wild-type VSV-G (wild-type VSV-G gene), and the LVV-VSVG is injected into the tail vein of mice.

[0120] I. Packaging LVV-VSVG

[0121] A. Prepare a 4-plasmid LVV packaging system

[0122] Prepare the following four plasmids: pMD2.G envelope plasmid (containing the wild-type VSV-G gene), pMDLg / pRRE packaging plasmid, pRSV-REV packaging plasmid, and shuttle plasmid VSV-G; the shuttle plasmid VSV-G contains the wild-type VSV-G gene, and a schematic diagram of the gene elements contained in the shuttle plasmid VSV-G is shown in Figure 1; as shown in Figure 1, between the 5' end and the 3' end LTR, there is the EF1α promoter, the wild-type VSV-G gene, IRES (encoding the internal ribosome entry site), and the GFP gene.

[0123] The amino acid sequence of the wild-type VSV-G containing its signal peptide is shown in SEQ ID NO:15.

[0124] B. Packaging LVV-VSVG

[0125] Packaging (a) a viral envelope containing the wild-type VSV-G; and (b) an LVV-VSVG carrying the shuttle gene, the wild-type VSV-G gene, specifically comprising the following steps:

[0126] Preparing packaging cells, HEK-293T cell culture system, packaging pseudotype LVV:

[0127] Take 56 mL of FBS, filter it into 500 mL of DMEM / high glucose (10% FBS), add 4 mL of P / S (double antibiotic, penicillin × streptomycin), shake well, and place in a carbon dioxide incubator for preheating and neutralization before transfection.

[0128] Day 0, HEK-293T cells were seeded at a density of 4.5 × 10⁴ cells in a 10 cm culture dish. 6 Approximately 48 hours after inoculation, when the cell confluence reached 80-90%, the four plasmids were transfected into HEK-293T packaging cells using PEI reagent, including:

[0129] Add 9 μg of shuttle plasmid VSV-G, 4 μg of pMDLg / pRRE packaging plasmid, 2 μg of pRSV-REV packaging plasmid, and 2 μg of pMD2.G envelope plasmid to 1 mL of Opti-MEM medium. After shaking well, add 64 μL of PEI reagent, mix well by pipetting, and let stand for 10 minutes. Then add to HEK-293T cell culture system. Replace the medium after 6 hours. Collect the supernatant of the medium 48 hours after transfection, filter it through a 0.45 μm filter membrane, centrifuge at 50000g for 2.5 h, discard the supernatant, resuspend the LVV-VSVG in 200 μL of F12 medium, and store at -80℃.

[0130] II. Immunize mice to prepare anti-VSV-G antibodies.

[0131] Day 0, prepare 4 BALB / c mice (purchased from Guangdong Zhiyuan Biotechnology Co., Ltd.), and inject 1E7 TU (Transducing unit, TU) of the LVV-VSVG into the tail vein of 3 of the mice (M1, M2, M3);

[0132] On Day 14, plasma was collected from each mouse, and the binding of antibodies to the VSV-G antigen in the plasma of each group of mice was detected using ELISA (enzyme-linked immunosorbent assay). A commercially available VSV-G antibody was used as a standard for comparison. Specific methods included:

[0133] I. Reagent Preparation:

[0134] 1. Coating buffer: 0.05 mol / L carbonate buffer (pH 9.6), consisting of: 0.75 g sodium carbonate, 1.46 g sodium bicarbonate and 500 mL Wahaha purified water;

[0135] 2. Washing solution: 8g sodium chloride, 1.14g anhydrous disodium hydrogen phosphate, 0.2g potassium chloride, 0.24g potassium dihydrogen phosphate, 500µL Tween-20 and 1000mL Wahaha purified water;

[0136] 3. Blocking solution: 2% BSA, 1g BSA and 50mL washing solution;

[0137] 4. Diluent: 0.1% BSA, 1 mL blocking buffer, and 20 mL washing buffer;

[0138] 5. Termination solution: 2M sulfuric acid, 20mL concentrated sulfuric acid, and 180mL Wahaha purified water;

[0139] II. Operating Procedures:

[0140] 1. Coating: 1µg / mL, 100µL / well, 4℃, overnight (12 hours (h));

[0141] 2. Washing: 1 minute / cycle, 300µL / well washing solution;

[0142] 3. Sealing: 200µL blocking solution / well, seal at room temperature for 2 hours;

[0143] 4. Washing: 1 min / wash, 300 µL / well washing solution;

[0144] 5. Sample loading: 100µL / well, incubate at room temperature for 1 hour;

[0145] 5.1 Preparation of standard (commercially available VSV-G antibody) is shown in Table 1 below.

[0146] Table 1

[0147] S1 30µg / mL 2*30ng / mL 0.6µL S1 + 600µL diluent S3 15ng / mL 300µL S2 + 300µL diluent S4 7.5ng / mL 300µL S3 + 300µL diluent S5 3.75ng / mL 300µL S4 + 300µL diluent S6 1.875ng / mL 300µL S5 + 300µL diluent S7 0.9375ng / mL 300µL S6 + 300µL diluent S8 0.46875ng / mL 300µL S7 + 300µL diluent S9 * 0ng / mL diluent

[0148] 5.2 Sample preparation: The plasma of each mouse was diluted 8000 times and 16000 times, respectively;

[0149] 6. Washing: 2 min / wash, 4 washes, 300 µL / well washing solution;

[0150] 7. Secondary antibody incubation: The working concentration of the secondary antibody (mouse-derived) is 250 ng / mL, 100 µL / well, incubated at room temperature for 1 h;

[0151] 8. Washing: 2 min / wash, 5 washes, 300 µL / well washing solution;

[0152] 9. Color development: 100µL color development solution / well, incubate at room temperature until the standard shows a clear color gradient, then stop (10-30 min).

[0153] 10. Termination: 100µL / well stop solution;

[0154] 11. Microplate reader: Absorption light, 450nm / 630nm.

[0155] III. Reagents and Consumables:

[0156] The brands and product numbers of the reagents and consumables used in ELISA testing are shown in Table 2 below.

[0157] Table 2

[0158] Reagent Name Brand Catalog Number Coated VSV-G Protein / (Custom) / Commercially Available Anti-VSV-G Antibody SIGMA-ALDRICH MABF2337-100ug Secondary Antibody (Mouse Derivative) JACKSON IMMUNORESEARCH 109-035-098 Chromogenic Solution Aladdin T117926-500ml Stop Solution / /

[0159] In Table 2, the coated VSV-G protein (amino acid sequence as shown in SEQ ID NO:18) is an antigen synthesized by Beijing Yiqiao Shenzhou Technology Co., Ltd. (compared to other proteins that can be expressed, synthesized and purified in vitro (the yield of synthesized and purified protein is about 10 mg), the coated VSV-G protein was only synthesized and purified to obtain 0.2 mg); the polynucleotide encoding the coated VSV-G protein sequentially encodes from the 5' end to the 3' end: wild-type VSV-G signal peptide, wild-type VSV-G extracellular domain, and 10×His tag.

[0160] IV. Experimental Results:

[0161] The OD values ​​(absorbance) of each well were read using an ELISA reader. The OD values ​​of each well after diluting the plasma of each mouse to 8000 times or 16000 times are shown in Figure 2A and Figure 2B, respectively.

[0162] As shown in Figures 2A and 2B, compared to the control group mice (CTR) that were not given the LVV-VSVG, IgG antibodies were detected in the plasma of mice in each experimental group (M1, M2, M3). This demonstrates that administering the LVV-VSVG to mice can effectively deliver and express the wild-type VSV-G gene in mice, thereby immunizing mice to prepare anti-VSV-G antibodies. This may be because the LVV-VSVG can (a) enter LDL-R+ cells, such as hepatocytes, adrenocortical cells, and macrophages, through endocytosis triggered by the specific binding of the viral glycoprotein VSV-G contained in its viral envelope to its receptor LDL-R, and deliver and express the wild-type VSV-G gene; or (b) be phagocytosed by cells with phagocytic capabilities, such as hepatocytes or spleen cells, and deliver and express the wild-type VSV-G gene. In particular, spleen cells contain various B cell subsets, which differentiate into plasma cells after being activated upon encountering antigens, participating in the antibody preparation process, which helps to prepare antibodies in animals.

[0163] III. Flow cytometry detection of antibodies in mouse plasma

[0164] The expression of IgG antibodies in the plasma of each mouse was detected by flow cytometry. The specific steps included:

[0165] On Day 14, 50 µL of plasma was collected from each mouse and co-incubated with Jurkat target cell line overexpressing wild-type VSV-G (construction method known to those skilled in the art). After washing once, the cells were incubated with secondary antibody (INVITROGEN, catalog number: #A11004).

[0166] The positivity rate of IgG antibodies in the plasma of each mouse was detected by flow cytometry, and the results are shown in Figure 3.

[0167] As shown in Figure 3, compared with the control group mice that were not injected with the LVV-VSVG (antibody positivity rate of approximately 2.55%), the plasma IgG antibody positivity rates of the three mice injected with the LVV-VSVG were approximately 99.26%, 98.19%, and 98.02%, respectively.

[0168] This further demonstrates that for VSV-G, which is difficult to express and purify in vitro (possibly due to its hydrophobic transmembrane domain), injecting a lentiviral vector carrying the wild-type VSV-G gene into the tail vein of mice can effectively express VSV-G in vivo, thereby immunizing the mice and preparing anti-VSV-G antibodies. Example 2

[0169] The LVV (LVV-BCMA) package contains a polynucleotide encoding human BCMA (BCMA gene), and the LVV-BCMA is injected into the tail vein of mice;

[0170] Human BCMA, amino acid sequence as shown in SEQ ID NO:17, UniProtKB number: Q02223.

[0171] I. Packaging LVV-BCMA

[0172] Prepare the following four plasmids: mutant envelope plasmid 1, pMDLg / pRRE packaging plasmid, pRSV-REV packaging plasmid, and shuttle plasmid BCMA; the shuttle plasmid BCMA contains the BCMA gene, and a schematic diagram of the gene elements contained in the shuttle plasmid BCMA is shown in Figure 4; as shown in Figure 4, between the 5' end and the 3' end LTR, there is the EF1α promoter, the BCMA gene, the IRES gene, and the GFP gene.

[0173] The mutant envelope plasmid 1 contains a mutant VSV-G1 with the amino acid sequence shown in SEQ ID NO:3. Compared to SEQ ID NO:1 (wild-type VSV-G), SEQ ID NO:3 contains a K47 deletion, which results in the inhibition of the ability of the mutant VSV-G1 to specifically bind to LDL-R, but retains the ability to mediate membrane fusion and endosome / lysosome escape.

[0174] LVV-BCMA is packaged according to the method for packaging the LVV-VSVG described in Example 1.

[0175] II. Immunizing mice

[0176] Day 0, prepare 5 BALB / c mice, and inject 1E7 TU of LVV-BCMA into the tail vein of 4 of them (M1, M2, M3, M4);

[0177] On Day 14, 50 µL of plasma was collected from each mouse and co-incubated with Nalm target cell lines overexpressing BCMA. After washing once, the cells were incubated with secondary antibody (INVITROGEN, catalog number: #A11004). The IgG antibody positivity rate in the plasma of each mouse was detected by flow cytometry. The results are shown in Figure 4.

[0178] As shown in Figure 4, compared with the control group mice that were not injected with the LVV-BCMA (IgG antibody positivity rate of 3.28%), the IgG antibody positivity rates in the plasma of the four mice (M1, M2, M3, and M4) injected with the LVV-BCMA were 99.60%, 99.86%, 99.94%, and 99.92%, respectively.

[0179] This demonstrates that injecting a lentiviral vector carrying the BCMA gene into the tail vein of mice can effectively express BCMA in mice, immunize the mice, and thus prepare anti-BCMA antibodies. This may be because the LVV-BCMA can be phagocytosed by cells with phagocytic capabilities in mice, such as hepatocytes and spleen cells, and enter the cells to deliver and express the BCMA gene, effectively immunizing the mice to prepare anti-BCMA antibodies. Example 3

[0180] CD19 was constructed according to the content of Example 1 above (refer to the plasmid map shown in Figure 6), and LVV (LVV-CD19) containing the polynucleotide (CD19 gene) encoding human CD19 was packaged. The difference from the above example is that the VSVG used in this envelope plasmid contains a second mutation that enhances the ability to antagonize complement inactivation: T214N and T352A; the amino acid sequence of human CD19 in the shuttle plasmid is shown in SEQ ID NO:19, human CD19: Uniprot ID:P15391.

[0181] Furthermore, the LVV-CD19 was injected into the tail vein of mice to immunize them and prepare anti-CD19 antibodies. Blood was collected from the orbital sinus of the immunized mice on Day 7 and Day 14, and mouse serum was obtained. The endpoint titer of the mouse serum antibodies was detected by indirect ELISA using the corresponding antibodies.

[0182] (1) Plate coating: Coat 96-well plates with His-tagged antigen protein at a concentration of 1 μg / mL, 100 μL per well, and incubate overnight at 4°C.

[0183] (2) Washing: After coating for 24 hours, discard the coating solution, add 300 μL of PBST to each well, and incubate at room temperature for 2 min, for a total of five times.

[0184] (3) Blocking: 300 μL of blocking solution (1% BSA) per well, incubated at 37°C for 1 h.

[0185] (4) Washing: Same as step (2).

[0186] (5) Blood was collected from the orbital sinus of immunized mice, and serum from the mice to be tested was obtained. Serum from unimmunized normal mice was used as a negative control. The serum from the mice to be tested and the negative control serum were serially diluted. The D7 dilution gradients were set as follows: 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, and 1:12800, for a total of 8 dilution gradients, with 2 replicates for each dilution. The D14 dilution gradients were set as follows: 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, and 1:25600, for a total of 8 dilution gradients.

[0187] (6) Primary antibody incubation: 100 μL of the serum diluted in the previous step is added to each well and incubated at 37°C for 1 h.

[0188] (7) Washing: Same as step (2).

[0189] (8) Secondary antibody incubation: 100 μL of HRP Goat Anti-Mouse solution diluted 1:5000 per well, incubated at 37°C for 40 min.

[0190] (9) Washing: Same as step (2).

[0191] (10) Color development: 100 HLTMB color development solution per well, incubate at 37°C for 3~5 min.

[0192] (11) Termination: Add 100 μL of termination solution to each well.

[0193] (12) Reading: Read the value of OD450 of the microplate reader.

[0194] As shown in Figure 7, compared with the control group mice (negative) that were not given the LVV-CD19, IgG antibodies were detected in the serum of mice in each experimental group (M1, M2, M3). This demonstrates that LVV-CD19 given to mice can also effectively deliver and express the CD19 gene in mice, thereby immunizing mice to prepare anti-CD19 antibodies. Example 4

[0195] The shuttle plasmid BCMA was constructed according to the content of Example 1 above, and LVV (LVV-BCMA) containing a polynucleotide (BCMA gene) encoding human BCMA was packaged. The LVV-BCMA was then injected into the tail vein of mice to immunize the mice and prepare anti-BCMA antibodies. Blood was collected from the orbital sinus of the immunized mice on Day 7 and Day 14, and mouse serum was obtained. The endpoint antibody titer of the mouse serum was detected by indirect ELISA using the corresponding antibody.

[0196] Unlike the embodiments described above, the VSVG used in this envelope plasmid contains a second mutation, T214N and T352A, that enhances the ability to antagonize complement inactivation.

[0197] As shown in Figure 8, compared with the control group mice (negative) that were not given the LVV-BCMA, IgG antibodies were detected in the serum of mice in each experimental group (M1, M2, M3). This demonstrates that administering LVV-BCMA containing different VSVG mutations to mice can effectively deliver and express the BCMA gene in mice, thereby immunizing mice to prepare anti-BCMA antibodies.

Claims

1. A pseudotyped lentiviral vector (LVV) or retroviral vector (RVV) for preparing antibodies in a subject, characterized in that, Include: A. The pseudotyped LVV or RVV contains an exogenous polynucleotide encoding an antigen; and, B. The surface of the pseudo-LVV or RVV contains viral glycoproteins or their functional fragments, or variants (Mutated G), or modified G.

2. The pseudo-LVV or RVV as described in claim 1, characterized in that, The antigens described in A include at least one of: A) intracellular expressed antigens, B) cell surface expressed antigens, and C) secreted antigens.

3. The pseudo-LVV or RVV as described in claim 2, characterized in that, The intracellular expressed antigens described in A) include at least one of the following: MAGE family proteins, NY-ESO-1 (LAGE-1), WT1 (Wilms' tumor 1 protein), p53, hTERT (telomerase reverse transcriptase), tyrosinase, BCR-ABL, ETV6-AML, mutant Ras, HPV E6 / E7 protein, HIV Gag p24 protein, EBV EBNA1 protein, influenza virus nucleoprotein, and Survivin; The cell surface expressed antigens mentioned in B) include At least one of them; and / or The secreted antigens described in C) include at least one of VEGF (vascular endothelial growth factor), IL-2 (interleukin-2), TGF-β (transforming growth factor-β), APRIL (a proliferation-inducing ligand, TNFSF13), IL-1Ra (interleukin-1 receptor antagonist), IL-8 (CXCL8), CCL2 (MCP-1), IL-6, IFN-γ, and GM-CSF.

4. The pseudo-LVV or RVV as described in claim 1, characterized in that, The viral glycoproteins or their functional fragments, variants, or modifications described in section B are selected from: vesicular stomatitis virus glycoproteins or their functional fragments, variants, or modifications; Nipah virus (NiV) glycoprotein G or its functional fragments, variants, or modifications; measles virus glycoprotein H or its functional fragments, variants, or modifications; lentivirus glycoproteins or their functional fragments, variants, or modifications; rabies virus glycoprotein (RVG) or its functional fragments, variants, or modifications; and gibberish leukemia virus glycoprotein (GaLV). ) or its functional fragments or variants or modifications thereof, biphilic murine leukemia virus glycoprotein (MLV-A) or its functional fragments or variants or modifications thereof, feline endogenous virus (RD114) glycoprotein or its functional fragments or variants or modifications thereof, avian plague virus (FPV) glycoprotein or its functional fragments or variants or modifications thereof, Ebola virus (EboV) glycoprotein or its functional fragments or variants or modifications thereof, and T-cell choroid plexus meningitis virus (LCMV) glycoprotein or its functional fragments or variants or modifications thereof; Preferably, the vesicular stomatitis virus glycoprotein is selected from: vesicular stomatitis virus Indiana strain glycoprotein, vesicular stomatitis virus Cocal strain glycoprotein, vesicular stomatitis virus Maraba strain glycoprotein, vesicular stomatitis virus Morreton strain glycoprotein, vesicular stomatitis virus Alagoas strain glycoprotein, and vesicular stomatitis virus New... The following vesicular stomatitis virus (VSV) strains contain glycoproteins: Jersey, Carajas, Chandipura, Eptesicus, Isfahan, Jurona, Malpais, Perinet, Piry, Radi, Rhinolopus, and Yug Bogdanovac.

5. The pseudo-LVV or RVV as described in claim 4, characterized in that, The viral glycoprotein or its functional fragment, or its variant, or its modified form comprises: a. A first mutation that inhibits the ability of its receptor LDL-R to specifically bind; and / or, b. A second mutation that enhances the ability to antagonize complement inactivation.

6. The pseudo-LVV or RVV as described in claim 5, characterized in that, The viral glycoprotein is: The vesicular stomatitis virus (VSV) belongs to the Indiana strain glycoprotein (wild-type VSV-G), and the amino acid sequence of the wild-type VSV-G is shown in SEQ ID NO:1; or, the vesicular stomatitis virus (VSV) belongs to the Cocal strain glycoprotein (wild-type Cocal-G), and the amino acid sequence of the wild-type Cocal-G is shown in SEQ ID NO:

2.

7. The pseudo-LVV or RVV as described in claim 6, characterized in that, The first mutation site mentioned in a. is: 1) Substitution or deletion of amino acids at positions 8, 9, 10, 47, 50, 51, 183, 179, 180, 182, 184, 209, 347, 350, 352, 353 and / or 354 in SEQ ID NO:1 or SEQ ID NO:2; deletion of amino acids at positions 1-18, 19-36, 37-51, 314-384, 321-374, 331-364, 344-354 and / or 345-353; or, 2) After best global alignment with SEQ ID NO:1 or SEQ ID NO:2, the substitution or deletion of amino acids at positions 8, 9, 10, 47, 50, 51, 183, 179, 180, 182, 184, 209, 347, 350, 352, 353 and / or 354, and the deletion of amino acids at positions 1-18, 19-36, 37-51, 314-384, 321-374, 331-364, 344-354 and / or 345-353.

8. The pseudo-LVV or RVV as described in claim 6, characterized in that, The second mutation site mentioned in b. is: 1) Amino acids located at positions 50, 146, 214, and / or 352 of SEQ ID NO:1 or SEQ ID NO:2, or, 2) After optimal global alignment with SEQ ID NO:1 or SEQ ID NO:2, the amino acid located at positions 50, 146, 214 and / or 352 corresponding to SEQ ID NO:1 or SEQ ID NO:2; Preferably, the mutation at the site is selected from amino acid substitutions, deletions, and insertions.

9. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises a pharmaceutically acceptable excipient or carrier and a pseudo-LVV or RVV as described in any one of claims 1 to 8.

10. The use of any one of the pseudo-LVV or RVV according to claims 1 to 8 in the preparation of antibodies in a subject.

11. A method for preparing antibodies, characterized in that, This includes administering to a subject a pseudo-LVV or RVV as described in any one of claims 1 to 8 or the pharmaceutical composition as described in claim 9.

12. The method as described in claim 11, characterized in that, The administration method is selected from at least one of enteral routes, inhalational routes, topical and mucosal routes, parental routes, and modified-release and implantable methods; the parental routes include intravenous bolus, intravenous infusion, intramuscular (IM), subcutaneous (SC), intradermal (ID), intra-arterial (IA), intra-portal (PV), intraosseous (IO), intraperitoneal (IP), intrapleural / thoracic (IT), epidural (EP), subarachnoid (IT), intracranial (IC), intraventricular (ICV), intra-articular (IA-aticular), intraocular (IVT), intralesional, and intratumoral administration.

13. The method according to claim 11, characterized in that, The subjects included humans (Homo sapiens), non-human primates (NHP), other mammals, and other vertebrates.

14. The method according to claim 13, characterized in that, The non-human primates include macaques (Macaca mulatta), chimpanzees (Pan troglodytes), cynomolgus monkeys (Macaca fascicularis), and rhesus monkeys (Macaca mulatta); the other mammals include mice (Musmusculus), rats (Rattus norvegicus), Chinese hamsters (Cricetulus griseus), rabbits (Oryctolagus cuniculus), cattle (Bos taurus), sheep (Ovis aries), goats (Capra hircus), Bactrian camels (Camelus bactrianus), alpacas (Vicugna pacos), and domestic horses (Equus ferus caballus); the other vertebrates include cartilaginous fish (Chondrichthyes).

15. The method according to any one of claims 11 to 14, characterized in that, This includes administering the pseudo-LVV or RVV to the subject no more than once, no more than twice, no more than three times, no more than four times, or no more than five times.

16. The method according to claim 15, characterized in that, This includes administering the pseudo-LVV or RVV to the subject once, twice, or three times.

17. A method for preparing antibodies, characterized in that, include: S1. Prepare antibodies in a subject using the method described in any one of claims 11 to 16; and S2. Collect the subject's bodily fluids, and separate and collect the antibodies from the bodily fluids.

18. The method according to claim 17, characterized in that, In S2, the body fluid includes blood and / or ascites.

19. The method according to claim 18, characterized in that, In S2, the bodily fluid is blood, and the method further includes: S21. Separate serum or plasma from the blood; and S22. Isolate and collect the antibody from the serum or plasma.

20. The method according to any one of claims 17 to 19, characterized in that, The method further includes: S3, purifying the antibody.